Driving T1D Breakthroughs

As the leading global type 1 diabetes (T1D) research and advocacy organization, JDRF helps make everyday life with T1D better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.

FY23 Mission Progress

Curing T1D is our north star. Until we have cures, we help people with T1D live healthier lives. And in the past year, we have seen incredible progress.

- **There are now 15 total devices approved by the FDA**, including the first tubeless AP system; other improved technologies such as the first FDA-approved algorithm for interoperability; and advanced insulins and drugs that work alongside insulin are helping to reduce dangerous highs and lows.
- **Cell Therapies** are in human clinical trials and so far, are yielding outstanding results. Multiple people have been able to stop taking insulin entirely.
- **Tzield™ (teplizumab-mzwv)**, a drug shown to delay onset of T1D for up to 3 years, is now the first FDA-approved disease-modifying therapy for T1D. Additional research shows that it helps preserve and protect beta cell health and function in people with new onset T1D.
- We have a diversified, global research strategy involving different kinds of cures and life-changing breakthroughs—all with multiple projects underway.

Leverage Leads the Way

A global leader in the pursuit of insulin therapy independence for people living with diabetes, JDRF accelerates the path to cures by raising funds and allocating them to T1D research and therapy development, and by leveraging our expertise and leadership to bring in additional funding and supporters. This leverage is a key part of our strategy to accelerate cures and life-changing breakthroughs. It has empowered us to grow global support of and investment in T1D research.

In FY23 we saw:

- **$449.4M** Total research support
  - **$138.4M** JDRF Research Funding and Investments
  - **$124.8M** Industry Partnerships and Investments
  - **$163.6M** U.S. and International Government Funding
  - **$22.6M** NGO and Other Funding

JDRF invested $138.4M in research in FY23, and through our influence within the public and private sectors, we helped raise another $311M. 

**A total of $449.4 million**—through funding from other organizations, corporations, and governments, in addition to JDRF—for T1D research and therapy development

Of that $449.4 million, the **T1D Fund**—our venture philanthropy fund established to address the lack of private investment in T1D therapy research and development—catalyzed **$94.9M** in private investment in companies developing T1D treatments.

*This $94.9M accounts for the majority of the $124.8M of the “Industry Partnerships and Investments” section in the triangle graphic.*
More than $1 Billion to Cures and Improving Lives

During the past five fiscal years, through our research grants and T1D Fund investments* (those that we have made, as well as private, alongside investments), more than $1 billion has been directed to cure T1D and improve lives—with most of it (approximately 82%) focused on cures.

*This is committed capital and includes tranched financings that may not have not had capital deployed yet.

FY23 JDRF Revenue

We have four main revenue streams: Events (Walk, Ride, Gala, etc.); Contributions (gifts, etc.); Investment Gains/Losses (T1D Fund and other investments), and International Affiliates/Other (funding raised by our five International Affiliates, other sources).

For FY23, we saw a nearly 15% increase in our total revenue over that of FY22.
FY23 Mission Spend

In FY23 we spent 37% more on advancing our mission than we did in FY22. This includes a 43% spending increase over FY22 for research funding and investments (grants, support, advocacy, and new T1D Fund investment), and a 23% spending increase over FY22 in public education/community engagement.

$138.4M
Research Funding and Investments
(grants, support, advocacy, new T1D Fund investments)

$183.9M
Advancing Our Mission

$45.5M
Public Education

T1D Fund

In 2016, a group of JDRF volunteers identified the need to attract more private investment for the development of T1D cure therapies. Their vision resulted in the creation of the T1D Fund, an impact investment fund that has used a venture philanthropic approach to catalyze more than $900 million of private investment in our mission and transformed the fight to cure T1D. The T1D Fund's unique approach to philanthropy relies on offering the global network and knowledge of JDRF and the Helmsley Charitable Trust as a resource for investors. This unparalleled source of expertise, delivered through a professional venture fund, has helped to create a bridge between research and commercial development and has helped activate the biotech industry. The FDA approval of Tzield and the cell therapies work being advanced by Vertex are examples of programs that benefited from early investment and support by the T1D Fund.

As of March 2024, the T1D Fund has invested ~$110 million in 43 companies and has attracted more than $800 million of private capital alongside it to be used in T1D programs. In addition, the T1D Fund’s investment strategy has resulted in more than $100 million of returns recycled back for future investment. Funded by more than $100 million in gifts from just over 100 donors and support from JDRF, in seven years the T1D Fund has become one of the largest disease-focused venture philanthropy funds in the world and the only one focused on T1D.

JDRF is a Charity Navigator four-star charity and is a Platinum Level Guide Star participant.